Ipsen appoints Mari Scheiffele as EVP and President, Specialty Care International
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211010005020/en/
Mari Scheiffele (Photo: Business Wire)
Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Mari Scheiffele as EVP and President, Specialty Care International, effective November 1st 2021. Based in Boulogne, France, she will be reporting directly to David Loew, CEO, Ipsen, and serve on the Executive Leadership Team.
“Along with the ELT, we are very pleased to welcome Mari to Ipsen. Her diverse experience will be critical in developing our three key therapeutic areas, Oncology, Rare Disease and Neuroscience, by continuing to strengthen Ipsen’s international commercial presence in over 115 countries, excluding North America. Mari also brings valuable capabilities in transformation which she built over the course of her previous roles at Novartis and McKinsey. We are looking forward to working closely with her,” said David Loew, CEO, Ipsen.
Mari brings 20 years of healthcare leadership experience, from across the industry, having worked in the US, Europe and in Japan. She joins Ipsen from Novartis where she has been in both global strategic and country operational roles, first in Japan and then in the UK. Most recently, Mari has been General Manager, Novartis Oncology UK & Ireland where with a focus on patient-centricity, evidence-based medicine, and partnership, she has driven a successful business transformation.
In addition to her depth in Oncology, Mari has worked in other specialty care environments such as ophthalmology, neuroscience and immunology. Prior to Novartis, Mari was a partner at McKinsey & Company in New York and in Switzerland in Pharmaceuticals and Medical Products.
“I’m delighted to be joining Ipsen at such an exciting time,” said Mari Scheiffele. “Ipsen has an inspiring strategy, strong growth and a fantastic culture of collaboration, and excellence. I look forward to working with my new colleagues on Ipsen’s International team, across its broad reach of markets, to bring Ipsen’s transformative innovations to patients around the World.”
Mari speaks English, Finnish and Japanese and holds a doctorate in neuroscience from Harvard Medical School.
Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience; it also has a well-established Consumer Healthcare business. With total sales of over €2.5bn in FY 2020, Ipsen sells more than 20 medicines in over 115 countries, with a direct commercial presence in more than 30 countries. The Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has around 5,700 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.
The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s 2020 Universal Registration Document, available on ipsen.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Executive Vice President, Communications and Public Affairs
+44 7876 391 429
Global Communications Director
+ 33 6 08 91 92 55
Vice President, Investor Relations
+44 7584 349 193
Adrien Dupin de Saint-Cyr
Investor Relations Manager
+33 6 64 26 17 49
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IPS acquires Linesight and partners for strategic growth18.10.2021 16:00:00 CEST | Press release
IPS-Integrated Project Services, LLC, headquartered in Blue Bell, Pennsylvania and a subsidiary of Alleghany Capital Corporation, today announced that it has acquired Linesight, a multinational consulting firm headquartered in Dublin, Ireland. IPS is a large EPCMV (Engineering, Procurement, Construction Management and Validation) company with over 1,700 staff across 22 offices worldwide. Linesight is a fast-growing professional consultancy services organization providing project controls to data center providers, life sciences companies, commercial real estate, healthcare, hospitality, retail and residential sectors. Linesight has over 900 staff across 24 offices globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005645/en/ The acquisition is being approached as a future integrated partnership where IPS will leverage Linesight’s experience and expertise in particular in the data center sector and Linesight in tur
Attensi og Eggs design vant innovasjonskontrakt med St. Olav. Skal lage neste generasjons trening for helsearbeidere og studenter innen psykisk helse18.10.2021 15:53:00 CEST | Pressemelding
Gode ferdigheter i å «lese», tolke og håndtere ulike møter med personer med psykiske lidelser tar tid å utvikle. For studenter og ansatte i fagfeltet psykisk helse er det utfordrende å få gjennomført tilstrekkelig mengdetrening i tillegg til møter med ekte pasienter. I løpet av de neste 12 månedene vil rundt 20 prosent av befolkningen i Norge ha utviklet en psykisk lidelse (kilde FHI), og riktig vurdering og håndtering er kritisk for en god bedringsprosess. Derfor skal neste generasjons opplæringsløsning nå utvikles, der helsepersonell gjennom bruk av spillelementer og avatarer skal få reell mengdetrening i å observere og videreformidle observasjoner om psykiske utfordringer. Krevende å vurdere riktig Det er et stort antall helsepersonell som er involvert i utredning, diagnostikk og behandling av personer med psykiske lidelser, og det kan være en krevende oppgave. Studenter innenfor helsefag oppgir ofte praksis knyttet til fagområdet psykisk helse som noe de opplever som spesielt kreve
Sumitomo SHI FW (SFW) Add CADMATIC Solutions to Further Support Digitalization, Data-driven Engineering, and Project Management18.10.2021 15:29:00 CEST | Press release
SFW is a provider of power, energy storage and environmental technologies and services for the global energy industry and has now entered into an agreement with CADMATIC Ltd to implement CADMATIC 3D plant design and information management solutions in their engineering projects in Finland, Poland, India, and China. The goal of the investment is to shorten lead times in design, engineering, and construction, improve the quality of design, and harmonize working methods across its international office network and subcontractors. The design and construction of a power plant is an extremely complex process that requires the integration of multiple design, engineering and construction disciplines, and many suppliers. CADMATIC software is an important element to streamline the process from design and engineering to construction and production and seamlessly integrate multiple parties in one project. Technical advantages in 3D Design, work-sharing, information management, and visualization wer
Deel Raises $425M in Series D Funding to Continue Transforming the Future of Work18.10.2021 14:45:00 CEST | Press release
Deel, the remote hiring company shattering job barriers worldwide, announced today that it has raised $425 million in Series D funding, taking the total amount raised by the company to over $630 million. The latest funding round values the company at $5.5 billion. Deel has become the highest valued company in the global hiring, payments, and compliance space with this investment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005567/en/ Deel Interface (Graphic: Business Wire) This new funding round was led by US-based Coatue, with partners Rahul Kishore and Lucas Swisher leading the deal. Several new and existing investors also participated in this round, including Altimeter Capital, Andreessen Horowitz, the YC Continuity Fund, Spark Capital, Greenbay Ventures, Neo, and over 40 of the world’s leading operators. Since Deel’s inception in 2019, the team - growing from four to 400 employees - has been on a mission to make
William Shatner Launches Everbridge’s ‘Unlocking Resilience’ Global Leadership Podcast Series, Available Today18.10.2021 14:30:00 CEST | Press release
Everbridge, Inc. (NASDAQ: EVBG) today announced the launch of its podcast Unlocking Resilience™: Global Leadership Seriesfeaturing William Shatner as its inaugural guest. The first-of-its-kind podcast features global influencers, government leaders, C-level executives and top healthcare experts as they discuss the confluence of leadership, technology and resilience at both the personal and organizational level. Topics will include overcoming personal challenges to create a life of resilience; effective strategies for building organizational resilience and business continuity in the face of critical events; and perspectives on the future of work, life and entertainment in a post-pandemic world, among other topics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005565/en/ William Shatner Launches Everbridge’s ‘Unlocking Resilience’ Global Leadership Podcast Series, Available Today (Graphic: Business Wire) The Unlocking R
Ferring to Present Award-Winning, Real-World Outcomes Analysis for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection and IBD at ACG 202118.10.2021 14:00:00 CEST | Press release
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced they will present data from two new retrospective analyses as part of American College of Gastroenterology’s Annual Scientific Meeting & Postgraduate Course (ACG 2021). The congress will take place in Las Vegas from October 22 – 27, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005060/en/ Eligibility criteria in CDI clinical trials often are narrowly defined, excluding broader patient populations. The first presentation will explore key health outcomes of RBX2660, an investigational microbiota-based live biotherapeutic for reduction of recurrent C. difficile infection (CDI), among patients in a real-world setting. The second analysis evaluates healthcare resource utilization and medical costs among Medicare patients with CDI with or without inflammatory bowel disease (IBD) as a comorbidity. Notably, one of the presentations has received The
Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes18.10.2021 13:30:00 CEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive Day 90 data for the first patient from the Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D). This is the first demonstration of a patient with T1D achieving robust restoration of islet cell function from such a cell therapy. The patient was treated with a single infusion of VX-880 at half the target dose in conjunction with immunosuppressive therapy. The patient achieved successful engraftment and demonstrated rapid and robust improvements in multiple measures, including increases in fasting and stimulated C-peptide, improvements in glycemic control, including HbA1c, and decreases in exogenous insulin requirement. VX-880 was generally well tolerated. “These results from the first patient treated with VX-880 are unprecedented. What makes these results truly remarkable is that they were ac